Martina Vendrame, Annapurna Poduri, Tobias Loddenkemper, Gerhard Kluger, Giangennaro Coppola, Sanjeev V Kothare
Index: Epileptic Disord. 13(1) , 18-21, (2011)
Full Text: HTML
The syndrome of malignant migrating partial seizures of infancy (MMPEI) is characterized by early onset of multiple seizures types, highly pharmaco-resistant seizures, and overall poor prognosis. In this study, we investigated retrospectively the efficacy of rufinamide (RUF) in five infants with MMPEI, by examining seizure type and frequency, EEG features and antiepileptic drug use. The data demonstrate that two of the five patients showed good efficacy and tolerability for RUF with a > 50% reduction in seizure frequency. The use of RUF for the treatment of MMPEI may therefore provide some hope for such infants and should be further validated. [Published with video sequences].
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Rufinamide
CAS:106308-44-5 |
C10H8F2N4O |
|
Dose-dependent pharmacokinetics and brain penetration of ruf...
2015-02-20 [Eur. J. Pharm. Sci. 68 , 106-13, (2015)] |
|
Toxicological screening of human plasma by on-line SPE-HPLC-...
2015-06-01 [Biomed. Chromatogr. 29 , 935-52, (2015)] |
|
Rufinamide for the treatment of Lennox-Gastaut syndrome.
2011-04-01 [Expert Opin. Pharmacother. 12(5) , 801-6, (2011)] |
|
Bioavailability of three rufinamide oral suspensions compare...
2011-01-01 [Clin. Ther. 33(1) , 146-57, (2011)] |
|
Rufinamide from clinical trials to clinical practice in the ...
2011-05-01 [Epileptic Disord. 13 Suppl 1 , S27-43, (2011)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
